Overview

A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension and Chronic Kidney Disease (CKD).
Phase:
Phase 2
Details
Lead Sponsor:
CinCor Pharma, Inc.
Collaborator:
Parexel